EHA 2025 | Long-term outcomes of patients with APL treated with ATO plus ATRA in the GIMEMA APL0406 study
Alfonso Piciocchi, MS, GIMEMA Foundation, Rome, Italy, comments on long-term outcomes of patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide plus all-trans retinoic acid (ATO plus ATRA) in the GIMEMA APL0406 study (NCT03096496). Mr Piciocchi highlights that this treatment regimen potentially restores normal life expectancy in patients with low and intermediate-risk APL. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, based on long-term follow-up data of the GIMEMA APL 0406 study, patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid appear to achieve normal life expectancies. In this cohort of 129 patients with a median follow-up of over 5 years, only two deaths were observed, compared to 2.24 expected based on population-level mortality rates...
Yes, based on long-term follow-up data of the GIMEMA APL 0406 study, patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid appear to achieve normal life expectancies. In this cohort of 129 patients with a median follow-up of over 5 years, only two deaths were observed, compared to 2.24 expected based on population-level mortality rates. The resulting standardized mortality ratio was less than 1, 0.89, with a confidence interval that includes 1, indicating no statistically significant difference from the general population. And these findings suggest that the ATO plus ATRA can induce durable remission and potentially restore normal life expectancy in low and intermediate risk APL patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
